() NKT News

NiKang Therapeutics

An early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs

News and Events

May 3, 2022 - NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China Read More

April 8, 2022 - NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152’s Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022 Read More

January 5, 2022 - NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma Read More

November 30, 2021 - NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma Read More

November 15, 2021 - NiKang Therapeutics Announces First Patient Dosed in A Phase 1/2 Study Evaluating NKT2152, a Small Molecule that Inhibits Hypoxia Inducible Factor 2α (HIF2α), for the Treatment of Advanced Clear Cell Renal Cell Carcinoma Read More

June 10, 2021 - NiKang Therapeutics Appoints Robert Xin, M.D., Ph.D., as Chief Medical Officer Read More

May 26, 2021 - NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets Read More

April 5, 2021 - NiKang Therapeutics Appoints Kelsey Chen, Ph.D., MBA, as Chief Financial Officer Read More

January 28, 2021 - NiKang Therapeutics Appoints Gary Yeung, CFA, to Board of Directors Read More

January 6, 2021 - Erasca announced the dosing of a first patient in December 2020 in Erasca’s FLAGSHP-1 study, a Phase 1/1b clinical trial to evaluate ERAS-601, a SHP2 inhibitor discovered and developed by NiKang Therapeutics Read More

September 14, 2020 - NiKang Therapeutics Completes $50 Million Series B Financing Read More

April 23, 2020 - Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment for Anti-Viral Diseases in China Read More